Opera phenix maintenance agreement for multiple units
Ended Purchase Order Awarded Last action
- Contract number
- 75N95022P00132
- Awardee
-
Revvity Health Sciences, Inc. UEI G2TETZJTELL4 Part of Revvity Inc.
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $350,842
Award facts
- Opportunity
-
- Opera Phenix Maintenance Agreement for Multiple Units Solicitation · 75N95022Q00114 · Posted Feb 8, 2022
- Contract value 100% obligated
- $350,841.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 811219 Other Electronic and Precision Equipment Repair and Maintenance
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $350,842 |
About this award
This firm fixed price purchase order for $350,841.84 was awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Revvity Health Sciences, Inc., a division of Revvity Inc. Medical Imaging, LLC, to provide maintenance agreements covering multiple units of high throughput microplate-based automated imaging systems. Specifically, the contract calls for gold service plans with preventative maintenance visits for seven Opera Phenix configurations, two Operetta CLS systems, one plate handler, and one Opera Phenix Plus system. These imaging systems will support ongoing stem cell growth and differentiation research as well as phenotypic screening conducted by the National Center for Advancing Translational Sciences. The period of performance is from February 22, 2022 through February 21, 2023 at the National Institutes of Health facilities located in Potomac, Maryland. There was no set-aside designation for this non-competitive award made under a combined synopsis/solicitation.
Quick answers
Who was awarded contract 75N95022P00132?
75N95022P00132 was awarded to Revvity Health Sciences, Inc. by National Institute on Drug Abuse (National Institutes of Health) on February 22, 2022.
How much is contract 75N95022P00132 worth?
The government has obligated $350,842 on 75N95022P00132.
Which agency awarded contract 75N95022P00132?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022P00132, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95022P00132 competed?
The extent of competition for 75N95022P00132 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award